Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCT-MSC in toddlers with autism spectrum disorder
NCT04294290Phase 1Completed
- Sponsor
- Duke University
- Start
- Feb 2021
- Primary completion
- Aug 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of wharton's jelly mesenchymal stromal cells in Autism Spectrum Disorder (ASD), sponsored by Duke University. Primary endpoints: Total Number of Infusion Reactions at 1 year, Severity of Infusion Reactions at 1 year and 11 more. Started Feb 2021; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04294290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294290.